Report from the annual general meeting of AroCell

The annual general meeting of AroCell AB (publ) was held on 3 June 2015. The following provides a summary of the resolutions passed. All resolutions were passed with the required majority.

4,627,983 (19.7 %) of the total of 23,460,960 shares were represented at the meeting.

The meeting passed a resolution to adopt the presented income statement and balance sheet. The meeting also passed a resolution to allocate the company’s loss in accordance with the Board of Directors’ proposal in the annual accounts. It was further resolved that no dividend would be paid for the 2014 financial year.

The general meeting passed a resolution regarding discharge from liability for members of the Board of Directors and the CEO.

The general meeting passed a resolution that the Board of Directors shall comprise five ordinary members and to appoint one auditor without a deputy.

The meeting passed a resolution that the board fee shall be SEK 150,000 for the chairman and SEK 50,000 for other board members. It was further resolved that the auditor’s fee shall be based on an approved invoice.

The general meeting passed a resolution to re-elect Erik Walldén, Håkan Englund, Staffan Eriksson and Jan Mellberg, and to elect Carl Blomqvist as a new member of the Board. Erik Walldén was appointed chairman of the Board of Directors.

The meeting re-elected Björn Ohlsson of Ernst & Young as auditor.

All the above elections relate to the period until the next annual general meeting.

The meeting passed a resolution to appoint a nominating committee ahead of the 2016 annual general meeting and adopted Instructions and rules of procedure for the nominating committee.

The meeting passed a resolution to authorise the Board of Directors to decide to implement a new issue of shares or other financial instruments in accordance with the proposal in the notice convening the meeting. The resolution was passed unanimously.

AroCell AB (publ) in briefAroCell AB (publ) is a Swedish company located in Uppsala. AroCell’s technology is based on an innovative method for measuring how quickly cells divide in the body, which can provide a measure of how aggressive a cancer tumour is. This is done using a simple blood sample and a laboratory test. The test, TK 210 ELISA, provides clinically valuable information for assessing prognosis, monitoring the effectiveness of cancer treatment, and treatment optimisation. The test is also ideal for following up and checking for possible recurrence. AroCell is listed on the AktieTorget marketplace in Sweden and has around 1,650 shareholders.

All of the information appearing on this website is not intended to be used for medical diagnosis or treatment. Information provided on this website does not either constitute medical and/or other professional advice.TK 210 ELISA is CE-marked and registered by the Swedish Medical Products Agency.